AI Article Synopsis
- Carbapenem-resistant organisms are becoming more common globally, especially in India, leading to high mortality rates in severe infections like bacteremia.
- Existing antibiotics, mainly carbapenems and polymyxins, have limitations but are still primary treatment options.
- Minocycline and tigecycline, both derived from the tetracycline class, are being re-evaluated for their potential effectiveness against multidrug-resistant organisms, although tigecycline has already seen frequent use despite its drawbacks.
Article Abstract
Carbapenem-resistant organisms are increasingly common worldwide, particularly in India and are associated with high mortality rates especially in patients with severe infection such as bacteremia. Existing drugs such as carbapenems and polymyxins have a number of disadvantages, but remain the mainstay of treatment. The tetracycline class of antibiotics was first produced in the 1940s. Minocycline, tetracycline derivative, although licensed for treatment of wide range of infections, has not been considered for treatment of multidrug-resistant organisms until recently and needs further in vivo studies. Tigecycline, a derivative of minocycline, although with certain disadvantages, has been frequently used in the treatment of carbapenem-resistant organisms. In this article, we review the properties of minocycline and tigecycline, the common mechanisms of resistance, and assess their role in the management of carbapenem-resistant organisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/mdr.2016.0043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!